The Centers for Medicare & Medicaid Services (CMS) is advancing the Medicare Advantage Qualifying Payment Arrangement Incentive (MAQI) Demonstration proposal to a public comment period and consideration for formal approval. If approved, the demo would waive Merit-Based Incentive Payment System (MIPS) requirements for clinicians who sufficiently participate in certain Medicare Advantage (MA) plans that involve assuming greater financial risk.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Data abstraction for ASCO’s Quality Oncology Practice Initiative (QOPI®) Round 2 of reporting opened on July 5 and will close on Tuesday, Dec. 4. Round 2 final reports will be available on Dec. 18.
In June 2018, ASCO President Monica M. Bertagnolli, MD, FACS, FASCO authored To Conquer Cancer, Our Nation Must Continue to Invest in Research, which focuses on the need for robust federal funding of cancer research.
ASCO and the European Society for Medical Oncology (ESMO), are calling on leaders and health ministers of the 193 United Nations (UN) member countries to reduce the burden of all non-communicable diseases (NCDs), including cancer. The two organizations issued a joint statement in advance of the third High-level Meeting of the United Nations (UN) General Assembly on the Prevention and Control of NCDs, taking place on September 27, 2018, in New York.
FDA has limited the use of Tecentriq (atezolizumab) and Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy. This is due to decreased survival associated with these drugs as single therapy (monotherapy) compared to platinum-based chemotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).
On Wednesday, June 27, the Trump Administration rejected the Massachusetts 1115 waiver amendment, a closed formulary plan that had the potential to limit access to new and innovative drug therapies by allowing the state to determine which drugs would be covered in its Medicaid program, MassHealth.
The Senate Appropriations Committee approved a $2 billion funding increase to the National Institutes of Health (NIH) as part of its Fiscal Year (FY) 2019 Department of Labor, Health and Human Services (HHS), Education funding bill.
ASCO is now accepting applications for the 2019-2020 cycle of its Health Policy Leadership Development program. The Health Policy Leadership Development Program, formerly known as the Health Policy Fellowship, is a one-year program that provides a meaningful and unique opportunity for ASCO members to develop expertise in health policy, advocacy, and grassroots activitiy.
On June 29, JCO Clinical Cancer Informatics (JCO CCI) published its second special collection of articles. This collection highlights new areas of digital health, providing a broad overview of the current state of technology in cancer care, as well as where the field may be headed in the future.
ASCO has launched a new ACT Network site that makes it easier-than-ever to advocate on behalf of the oncology community. As the online advocacy hub for ASCO advocates, the new ACT Network offers enhanced features that allow advocates to quickly and easily engage their lawmakers on key policy issues.
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (BRAFTOVI™ and MEKTOVI®, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
In the latest ASCO in Action Podcast, Dr. Edward Kim, Chair of the Department of Solid Tumor Oncology at the Levine Cancer Institute, joined ASCO CEO Dr. Clifford A. Hudis to discuss eligibility criteria for cancer clinical trials.
The American Medical Association (AMA) Opioid Task Force issued a report documenting physician-driven initiatives to advance the fight against the opioid epidemic in the United States, progress to date, and recommendations to continue to help reverse the epidemic. ASCO has been an active member of the AMA Opioid Task Force since 2017.
ASCO Practice Consulting Services & Support is expanding its offerings to include new clinical consulting services designed to help oncology practices standardize patient care, use their workforce efficiently, and transition patient care to a value-based care delivery model.
The Centers for Medicare & Medicaid Services (CMS) has provided an update on their review of a 2017 Wisconsin Physician Service Insurance Corporation (WPS)—a Medicare Administrative Contractor (MAC)—local coverage decision limiting off-label prescribing.